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Aim Failure rate to implant left ventricular (LV) lead transvenously is 4–8% in cardiac resynchronization therapy (CRT)
patients. Epicardial lead placement is an alternative method and if not applicable case reports and small series
showed the feasibility of endocardial LV lead implantation. Electroanatomical mapping might be a useful tool to
guide this procedure.
Methods
and results
Four patients had undergone endocardial LV lead implantation after unsuccessful transvenous implantation or epicar-
dial LV lead dysfunction using the transseptal approach. Electroanatomical mapping was used to mark the location of
the transseptal puncture. This location point guided the mapping catheter from the subclavian access and facilitated
positioning of the LV lead at the adjacent latest activation area of the left ventricle detected by activation mapping.
Endocardial active fixation LV leads were successfully implanted in all patients with stable electrical parameters im-
mediately after implantation and over a mean follow-up of 18.3 months (lead impedance 520+177 vs. 439+119 V
and pacing threshold 0.8+0.2 V, 0.5 ms vs. 0.6+0.1 V, 0.5 ms, respectively). Patients were maintained on anticoa-
gulation therapy with a target international normalized ratio of 3.5–4.5 and did not show any thromboembolic, haem-
orrhagic events, or infection. Echocardiography showed significant improvement of LV systolic function with marked
improvement of the functional status.
Conclusions Electroanatomical mapping is a useful technical tool to guide endocardial LV lead implantation. It helps to identify the
location of the transseptal puncture and the use of activation mapping might facilitate location of the optimal lead
positions during CRT.
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Introduction
Cardiac resynchronization therapy (CRT) is an effective non-
pharmacological treatment modality in patients with symptomatic
congestive heart failure (HF) refractory to medical therapy, left
ventricular (LV) dysfunction and wide QRS.1– 3 The standard ap-
proach is to implant the LV lead transvenously in one tributary
of the coronary sinus (CS). However, even with innovative lead
technology lead placement fails in 4–8%.2,4 Most frequent
reasons are CS occlusion, dissection, abnormal ostium of the CS,
coronary vein stenosis, lead instability, high threshold, or phrenic
nerve stimulation.2,5,6 Epicardial lead placement is an alternative
method which includes minimal-invasive thoracoscopy or lateral
thoracotomy, and usually requires general anaesthesia.7 When epi-
cardial LV lead implantation is contraindicated or at higher risk, LV
endocardial lead implantation might be considered.8
Cardiac resynchronization therapy is typically delivered with an
LV lead in a lateral or posterolateral position1– 3 and is placed in
the middle or distal portion of the side branch to ensure a
stable position. In contrast, when using the endocardial transseptal
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approach, the LV lead position is independent of the coronary
venous anatomy. The major difficulty of this method is to locate
the transseptal puncture site performed with a transfemoral ap-
proach from the subclavian access and to find the optimal position
of the LV lead within the LV cavity.
Electroanatomical mapping involves visualizing cardiac structures
and gathering data of the electrical activation of the heart. This
method is widely used to guide ablation procedures in the left
atrium (LA) as well as in the right ventricle and left ventricle.9
With the use of activation mapping we can record the activation
sequence of the heart. Electroanatomical mapping might be a
useful tool to guide endocardial LV lead implantation for CRT.
Patients
Four patients had undergone endocardial LV lead implantation at
our hospital between November 2007 and May 2010 guided by
electroanatomical mapping. Indications for CRT were in accord-
ance with the current guidelines.10 Patient characteristics are
listed in Table 1. All patients had left bundle branch block (LBBB)
or paced rhythm with LBBB-like morphology.
Cardiac resynchronization therapy was attempted or performed
either transvenously or epicardially as a first procedure. Patient 1
had an epicardial LV lead dysfunction, the second operation was
contraindicated, and the patient was referred for endocardial LV
lead implantation. Patients 2 and 4 had unsuccessful transvenous
LV lead implantation. Patient 3 had LV lead dysfunction after suc-
cessful transvenous LV lead implantation. In Patients 2 and 3, mini-
thoracotomy was contraindicated because of multiple co-
morbidities and a subsequent higher risk of surgical intervention.
Patients 1 and 4 did not give their consent for epicardial surgical
LV lead implantation. All patients had given informed consent
prior to the procedure.
Pre-implant echocardiography and tissue Doppler imaging
revealed severely depressed LV function and dyssynchronous acti-
vation pattern with a significant delay of the lateral (n ¼ 3) and the
posterolateral wall (n ¼ 1). Mitral regurgitation was evaluated by
colour Doppler imaging using a semi-quantitative method (grade
I– IV).
Methods
The LV endocardial lead implantation was performed using a combined
femoral and subclavian approach guided by electroanatomical mapping.
The first step of the procedure was to introduce the CARTO Quick
Star catheter (Biosense Webster, Diamond Bar, CA, USA) through
the right femoral vein to capture the anatomical map of the right
atrium and the right ventricle and the activation sequence of the
right ventricle. The transseptal puncture was performed with the guid-
ance of fluoroscopy and intracardiac echocardiography including con-
tinuous monitoring of the arterial pressure. Intravenous heparin was
given after the transseptal puncture (5000 IU); in case of long-lasting
procedures it was administered repeatedly to maintain an ACT level
of 250 ms.
After successful transseptal puncture, Quick Star catheter was intro-
duced into the transseptal sheath and the puncture point of the
septum was marked on the CARTO map (Biosense Webster) with a
pink dot, while the corresponding region was marked with white
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small dots (Figure 1). After removal of the Quick Star catheter, a guide-
wire (0.035 inch × 260 cm) was inserted into the LA and advanced
into the left upper pulmonary vein and an angioplasty balloon (6 mm
× 20 mm Maverick, Boston Scientific, Natick, MA, USA) was inserted
into the LA on the previously positioned guide-wire. The transseptal
sheath was withdrawn into the right atrium and the balloon was posi-
tioned across the septal puncture site. It was inflated 3 times with 12
atmospheres for 5 seconds before its removal. The transseptal sheath
was then positioned into the right atrial cavity.
The Quick Star deflectable catheter was introduced again into the
LA and advanced into the LV cavity via the right femoral vein. Left
atrial and LV anatomical and activation maps were recorded
(Figure 2). The latest activation of the left ventricle was localized at
the lateral wall in three patients and at the posterolateral wall in one
patient.
An 11 F-long sheath (SCOUT Pro 8 Fr, Biotronik GmbH&Co, Berlin,
Germany) was introduced via the left subclavian vein. The Quick Star
catheter was advanced into the sheath and directed to the location of
the previously marked transseptal puncture site applying CARTO map
guidance.
The long sheath was forced through the interatrial septum into the
LA and further into the left ventricle over the deflectable Quick Star
catheter. When the sheath did not go through the site of the puncture,
angioplasty balloon (6 mm × 20 mm Maverick, Boston Scientific,
Natick, MA, USA) was positioned to the puncture site through the
previously applied guide-wire from the femoral access and it was
inflated and deflated again, as needed. The Quick Star catheter was
used to relocate the LV segment with the latest activation. When
the latest activation site was found, the Quick Star catheter was with-
drawn into the sheath and the sheath was pushed against the LV wall to
ensure stable position. Active fixation LV leads were fixed at the basal
or mid-basal portion of the left ventricle in all patients where the
longest delays were detected on the activation map. Using the long
sheath pushed against the LV wall to have a stable support facilitated
the position of the LV lead close to the mitral valve. Standard
bipolar screw-in leads were used in all patients (Medtronic 5076–
65 cm, Medtronic, Minneapolis, MN, USA, n ¼ 4). The LV lead was
connected to the CRT device placed in the left pectoral area. The
atrial lead was implanted in the right atrial appendage in all patients.
The right ventricular lead was positioned in the right ventricular
septum (Figure 3A and B).
Data are presented as mean+ standard deviation. Changes in LV
pacing threshold, LV pacing impedance at implantation, and at last
patient visit were analysed using paired t-test. New York Heart Asso-
ciation (NYHA) functional class and mitral regurgitation were analysed
using the Wilcoxon’s signed rank test, as appropriate. Statistical signifi-
cance was considered at P, 0.05. Statistical analyses were performed
using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA,
USA).
Results
LV endocardial leads were successfully implanted in all patients.
Cardiac resynchronization therapy pacemaker was implanted in
one patient (Stratos LV-T, Biotronik GmbH&Co, Berlin,
Germany), while three patients received CRT-D devices (Cognis,
Boston Scientific, Miami, FL, USA, n ¼ 1; Concerto, Medtronic, n
¼ 1; Atlas HF, St Jude, Sylmar, CA, USA, n ¼ 1). Electrical para-
meters during device implantation were as follows: LV signal amp-
litude 8.5+ 3.0 mV, LV pacing threshold 0.78+ 0.18 V, impulse
width of 0.5 ms, and LV lead impedance 520+177 V. No
phrenic nerve stimulation occurred at 10 V, 0.5 ms with rapid LV
pacing (100 b.p.m.). The procedure times were 186, 165, 96, and
145 min, and fluoroscopy times were 45, 42, 23, and 32 min, re-
spectively (Figure 4).
Figure 1 Patient 1. CARTO image, antero-posterior projec-
tion. The location of the transseptal puncture is indicated with
a single white arrow on the CARTO map.
Figure 2 Patient 1. CARTO image, left lateral projection. Right
and the LV activation map: the earliest activation site is the right
ventricular anteroseptal region; the latest site is the mid-basal
part of the posterolateral wall.
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In all patients, the international normalized ratio was maintained
between 3.5 and 4.5 as for those with mechanical valve prostheses
and high thrombotic risk. Neither pericardial fluid nor intracardiac
thrombi were observed during echocardiography in the early post-
operative period or during follow-up. Neither major haematoma
nor significant post-procedural bleeding occurred. During the
mean follow-up of 18.3 months, stable sensing and pacing para-
meters were found. The mean LV pacing threshold was 0.6+
0.1 V at impulse width of 0.5 ms (P ¼ 0.44), LV lead impedance
was 439+119 V (P ¼ 0.12).
We did not observe lead dysfunction, insulation failure, or dis-
location of the LV lead. There were no signs of lead infection
during the follow-up period. Heart failure symptoms improved at
least one NYHA class in all patients, LV systolic function improved
significantly from a mean LV ejection fraction of 28+5.2 to 41+
6.6% (P ¼ 0.015). The grade of mitral regurgitation did not change
significantly during the follow-up period (P ¼ 0.28) (Table 1). Small
left–right shunt was detected in all patients immediately after the
procedure. We did not observe residual left–right shunts by trans-
thoracal echocardiography; no embolism, cyanosis, right-heart
failure was observed during the follow-up. No thromboembolic
or haemorrhagic events occurred.
Discussion
Difficulties may be encountered when attempting LV lead place-
ment during CRT. If transvenous LV lead placement via the CS is
not possible and epicardial approach is contraindicated, LV endo-
cardial lead implantation is an alternative method in selected
patients. Early case reports and small series showed the safety
and feasibility of this procedure. No report has shown the feasibil-
ity of electroanatomical mapping guidance during endocardial LV
lead implantation, yet.
The first successful endocardial LV lead implantation was
reported by Jais et al.11 in 1998 was performed via the right jugular
vein after a transfemoral interatrial septal puncture. Leclerq et al.12
described three cases of LV lead placement applying a transseptal
approach from the right jugular vein. Van Gelder et al.8 and Nuta
et al.13 developed a new technique, performing the transseptal
puncture via the femoral vein and positioning the LV electrode
from the subclavian vein into the LV cavity through the interatrial
septum and the mitral valve. In our study, we used the latter ap-
proach; however, electroanatomical mapping technique was used
additionally to enhance proper LV lead placement and facilitating
the LV lead implantation from a subclavian access. The implant-
ation time and also the fluoroscopy time was less than expected.
There are potential advantages of endocardial LV lead place-
ment compared with epicardial pacing. Endocardial LV lead pos-
ition is not limited by the anatomy of the CS. Experimental14
and clinical15 observations also suggested that endocardial pacing
is more physiologic than epicardial pacing. Garrigue et al.16 and
Jais et al.17 reported better haemodynamic results with higher
aortic and mitral time velocity integral, improvement of LV frac-
tional shortening and reduction of regional electromechanical
delay in patients with endocardial LV pacing. In our patient
Figure 3 Patient 4. Typical final lead positions in right-anterior
oblique projection and in left-anterior oblique projection. RA
lead, right atrial lead is positioned in the right atrial appendage;
RV lead, right ventricular lead is positioned in the right ventricular
apical septum; LV lead, LV lead is positioned in the mid-basal
portion of the lateral wall.
Figure 4 Procedure and fluoroscopy time.
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cohort, we also reported significant improvement of the LV systol-
ic function and a marked improvement of the patient’s functional
status during the long-term follow-up.
The drawbacks of this approach include the risk of transseptal
catheterization, the current lack of appropriate implantation
tools and the possible need for lifetime anticoagulation, as previ-
ously reported.8 However, anticoagulation is indicated in the ma-
jority of these patients due to severe LV systolic dysfunction
and/or the presence of atrial fibrillation. Long-term follow-up
data regarding thromboembolic or haemorrhagic complications
were so far not available. Our study showed that during
1.5-year follow-up no haemorrhagic or thromboembolic events
occurred.
Using the transseptal CRT approach, the LV lead crosses the
atrial septum, mitral valve and is actively fixed to the LV endocar-
dial surface. It is controversial whether mitral regurgitation might
be worsened with this technique: however, we did not observe
any worsening of mitral regurgitation or echocardiographic evi-
dence of the mitral valve being partially kept open. The risk of in-
fective endocarditis might be increased,18 but no data of more
frequent endocarditis are currently available in this patient popula-
tion. We did not observe any lead infection during the follow-up
period.
Transseptal punctures are associated with iatrogenic atrial septal
defects and concomitant left–right shunts.19 It is important to
evaluate this in patients with LV leads crossing the atrial septum.
In our study cohort, small left–right shunt was detected in all
patients immediately after the procedure. During follow-up, we
did not observe residual left–right shunts; however, it was diag-
nosed using two-dimensional transthoracal echocardiography,
and tranoesophageal echocardiography was not performed. We
used an 8F sheath for the transseptal puncture during the proced-
ure. Several earlier studies indicated that using 8F sheaths for trans-
septal punctures create iatrogenic atrial septal defects.19 The
incidence of atrial septal defects is as high as 87% immediately
after the procedure, while it is decreasing over time. At 6-month
follow-up, only 21% of iatrogenic atrial septal defects persisted.20
Residual septal defects are well tolerated and not associated
with increased risk of embolism, cyanosis or right-heart failure.19
We do not have additional information about the impact of
balloon dilatation on the incidence and persistence of atrial
septal defects in this patient population undergoing transseptal
CRT implantation. We assume that using balloon dilatation in
this highly mobile region of the atrial septum facilitates more
easy penetration in the short term while it is not associated with
larger atrial septal defects in the long term, therefore not expected
to be clinically relevant. In the future, serial transoesophageal echo-
cardiography studies are needed to further evaluate this.
Clinical studies showed appropriate positioning of the LV lead to
be of high importance to increase the number of CRT respon-
ders.21,22 Recent studies also demonstrated that an ‘individually’
based LV pacing approach compared with conventional CS
pacing, echo-guided or lateral area strategy might result in better
short-term haemodynamic response in non-ischaemic cardiomy-
opathy patients.23 The authors reported a benefit of endocardial
pacing. Our study also emphasizes the positive effects of endocar-
dial pacing.
Spragg et al.24 recently found that electroanatomical mapping
with colour-coded dP/dtmax response is a feasible approach to
identify LV endocardial sites with the highest peak of LV pressure
increase (dP/dtmax). Although only acute haemodynamic response
was evaluated in this study, optimal LV pacing site was more
often found in a basal location (in 8 of 11 patients). In our study,
electroanatomical activation mapping was used to identify the
latest activation area to find optimal LV lead position for CRT.
Functional assay (dP/dtmax) might be an alternative approach to
guide LV lead implantation and the two approaches may give dis-
cordant results.24 However, there is no direct comparison or long-
term data available yet.
Singh et al.25 showed that clinical benefit from CRT was similar
with LV leads along the anterior, lateral or posterior wall in mildly
symptomatic HF patients. However, LV leads positioned in the
apical region were associated with subsequent worse outcome.
Our study also supported the hypothesis that basal, mid-basal LV
lead position might be associated with a favourable echocardio-
graphic and clinical improvement during a mean follow-up of 1.5
years.
An alternative approach is reported to implant the LV lead
transapically with a minimally invasive surgical technique. This tech-
nique has the advantage of avoiding mitral valve crossing, but bears
a higher surgical and post-operative risk compared with our new
approach.26 However, our small cohort does not allow a real com-
parison with other techniques.
Because of the technical complexity of this technique, this ap-
proach remains a rare exception in CRT candidates and indicated
only if transvenous implantation is not successful. More patients
and longer follow-up are needed to provide additional data of
this approach.
Limitations of the report
This report includes four patients who had undergone electroana-
tomical mapping-guided transseptal endocardial LV lead implant-
ation. One of the major limitations of this report is the few
patients included, which did not allow us to compare this tech-
nique with the standard approach. The mean follow-up of 18.3
months is relatively short; however; earlier studies reported even
shorter follow-up periods. With this technique, the position of
the LV lead cannot be tracked within the LV cavity using the
CARTO electroanatomical mapping system.
Conclusion
We report successful electroanatomical mapping-guided LV endo-
cardial lead implantation in four patients after unsuccessful transve-
nous or epicardial LV lead placement. Electroanatomical mapping
to implant LV endocardial leads is proven to be useful in shortening
the procedure and fluoroscopy time by identifying the location of
the transseptal puncture. Activation map might help to identify the
optimal LV lead position for CRT. No major complications such as
bleeding, thromboembolism, or infections were observed. Pacing
parameters remained stable over long-term follow-up. Clinical
symptoms of HF and cardiac function improved significantly. We
conclude that transseptal endocardial LV lead implantation
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guided by electroanatomical mapping might be a feasible method
for CRT if transvenous LV lead placement is not possible. More
data are needed to assess the safety and long-term efficacy of
this new approach.
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